Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 13/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21588984 | 0.90 | MAPT (0.55) | KMT2AMEN1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL16071546 | 0.90 | MAPT (0.62) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL16653873 | 0.88 | TP53 (0.47) | KMT2AMEN1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL16665239 | 0.88 | MAPT (0.46) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL975415 | 0.83 | MAPT (0.59) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL5558333 | 0.82 | RAB9A (0.44) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL12466626 | 0.82 | MAPT (0.63) | KMT2AMEN1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL29523841 | 0.82 | MAPT (0.63) | KMT2AMEN1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL20836823 | 0.82 | ALDH1A1 (0.47) | KMT2AMEN1MAPTALDH1A1CYP1A2 | |
| SCHEMBL19633356 | 0.82 | KMT2A (0.38) | KMT2AMEN1MAPTALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440830-B2 | Tetrahydro-fused pyridines as histone deacetylase inhibitors | 4SC AG (DE) | 2013-05-14 | — | — | US | disclosed |
| EP-2197552-B1 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021494-A1 | NOVEL TETRAHYDRO-FUSED PYRIDINES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC3 | KMT2A 86/4885MEN1 3674/4885MAPT 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.